We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Read MoreHide Full Article
Key Takeaways
Keros reported a wider Q2 loss as service and other revenues fell to zero from $18.2 million a year ago.
Keros expects its cash resources to fund operations into H1 2028, supporting ongoing pipeline development.
Keros started a phase II DMD study for rinvatercept and expects initial data in the first half of 2027.
Keros Therapeutics (KROS - Free Report) reported second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share reported in the year-ago quarter.
Keros recorded no revenues, down 100% from $18.2 million a year earlier and in line with the Zacks Consensus Estimate.
KROS' Q2 Results in Detail
Keros does not have a marketed product and therefore lacks a regular source of revenues. The company periodically records service and other revenues as well as license revenues, making quarterly comparisons dependent on the timing of collaboration-related revenue recognition.
Service and other revenues were nil in the reported quarter compared with $18.2 million in the prior-year period. License revenues were also nil in both periods.
Year to date, Keros shares have plunged 50.3% against the industry’s 2% growth.
Image Source: Zacks Investment Research
Research and development expenses declined 48.7% year over year to $22.3 million. The decrease primarily reflected the transfer of elritercept-related development costs to Takeda and the corporate restructuring completed in 2025.
General and administrative expenses fell 40.6% year over year to $8.6 million. The decrease was due to lower professional fees and reduced compensation costs tied to the 2025 restructuring.
KROS' Cash Runway
Cash and cash equivalents totaled $257.6 million as of June 30, 2026, down from $281.5 million as of March 31, 2026.
Based on current operating assumptions, Keros expects its cash resources to fund operating expenses and capital expenditure requirements into the first half of 2028. The runway supports the ongoing development of rinvatercept as the company advances its clinical programs, with no recurring product revenues.
KROS’ Key Pipeline Updates
Keros initiated a phase II clinical study evaluating its lead candidate, rinvatercept, in patients with Duchenne muscular dystrophy (DMD). The milestone followed a phase I study in healthy volunteers in which the candidate demonstrated increases in muscle mass and bone mineral density, alongside a reduction in fat mass.
KROS continues to expect initial data from the phase II DMD study in the first half of 2027. Rinvatercept is also being developed for amyotrophic lateral sclerosis. The company plans to engage with regulatory authorities soon to discuss the design of a phase II study evaluating rinvatercept for this additional indication.
Keros’ most advanced candidate, elritercept, is in late-stage development for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Takeda holds exclusive rights to develop, manufacture and commercialize the candidate worldwide outside mainland China, Hong Kong and Macau.
Keros Therapeutics, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.30, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have lost 4.9% year to date.
Harmony Biosciences’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 25.16%.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 10.2% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 143.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Key Takeaways
Keros Therapeutics (KROS - Free Report) reported second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share reported in the year-ago quarter.
Keros recorded no revenues, down 100% from $18.2 million a year earlier and in line with the Zacks Consensus Estimate.
KROS' Q2 Results in Detail
Keros does not have a marketed product and therefore lacks a regular source of revenues. The company periodically records service and other revenues as well as license revenues, making quarterly comparisons dependent on the timing of collaboration-related revenue recognition.
Service and other revenues were nil in the reported quarter compared with $18.2 million in the prior-year period. License revenues were also nil in both periods.
Year to date, Keros shares have plunged 50.3% against the industry’s 2% growth.
Image Source: Zacks Investment Research
Research and development expenses declined 48.7% year over year to $22.3 million. The decrease primarily reflected the transfer of elritercept-related development costs to Takeda and the corporate restructuring completed in 2025.
General and administrative expenses fell 40.6% year over year to $8.6 million. The decrease was due to lower professional fees and reduced compensation costs tied to the 2025 restructuring.
KROS' Cash Runway
Cash and cash equivalents totaled $257.6 million as of June 30, 2026, down from $281.5 million as of March 31, 2026.
Based on current operating assumptions, Keros expects its cash resources to fund operating expenses and capital expenditure requirements into the first half of 2028. The runway supports the ongoing development of rinvatercept as the company advances its clinical programs, with no recurring product revenues.
KROS’ Key Pipeline Updates
Keros initiated a phase II clinical study evaluating its lead candidate, rinvatercept, in patients with Duchenne muscular dystrophy (DMD). The milestone followed a phase I study in healthy volunteers in which the candidate demonstrated increases in muscle mass and bone mineral density, alongside a reduction in fat mass.
KROS continues to expect initial data from the phase II DMD study in the first half of 2027. Rinvatercept is also being developed for amyotrophic lateral sclerosis. The company plans to engage with regulatory authorities soon to discuss the design of a phase II study evaluating rinvatercept for this additional indication.
Keros’ most advanced candidate, elritercept, is in late-stage development for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Takeda holds exclusive rights to develop, manufacture and commercialize the candidate worldwide outside mainland China, Hong Kong and Macau.
Keros Therapeutics, Inc. Price, Consensus and EPS Surprise
Keros Therapeutics, Inc. price-consensus-eps-surprise-chart | Keros Therapeutics, Inc. Quote
KROS’ Zacks Rank & Stocks to Consider
Keros currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) , Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.30, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have lost 4.9% year to date.
Harmony Biosciences’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 25.16%.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 10.2% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 143.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.